Nuclear Medicine Board Review
2025/2026 Exam Questions and Correct
Answers | New Update
Gas Ventilation - 🧠 ANSWER ✔✔Xe 133, 81 KeV, 5.3 half life; reactor
produced
dose: 10-20 mCi
imaging: posterior position
negative pressure room required
uses activated charcoal trap to accumulate the exhaled xenon gas until
decayed to background
single breath: during inhalation
wash in / equilibrium : collected while the xenon distributes through aerated
portions of the lung
,wash out : while radioactivity is cleared from lungs
Sr 89 Chloride - 🧠 ANSWER ✔✔Strontium Chloride, Metastron
1.46 MeV max, .58 Mev mean
half life = 50.5 days
40-60 uci/kg IV
for skeletal mets, depresses bone marrow
shouldn't be used if leukocyte count below 2400/ul or platelet below
60,o00/ul
excretion : urinary
I 131 Tositumomab - 🧠 ANSWER ✔✔Bexxar
half life = 8.04 days
606.3 KeV max energy
treatment of patients with NHL
before treatment, patient must receive 650 mg acetaminophen and 50mg
diphydramine orally
thyroid uptake should be minimized with SSKI
,activity initially seen in blood pool, liver and spleen
later times, activity in liver, spleen, thyroid, bladder, and tumor sites
Y 90 ibritumomab tiuxtetan - 🧠 ANSWER ✔✔Zevalin
half life = 2.67 days
2.281 MeV
treatment of patients with NHL (disseminated follicular B-Cell)
monoclonal antibody against lymphoma antigens
before treatment, patient must receive 650 mg (imaging) acetaminophen
and 50mg diphydramine orally
max dose = 32 mci
platelets must be at least 100,000/mm3
Sm 153 EDTMP - 🧠 ANSWER ✔✔ethylenediaminetetra methylene
phosphonic
Quadramet
half life = 46.7 hours
0.81 MeV maximum
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
PRIVACY STATEMENT. ALL RIGHTS RESERVED
, concentrates in bone marrow
for patients with more metabolically activate metastases from prostate or
breast cancer, as well as those from osteogenic sarcoma
1.0mci/kg
urinary excretion
Bone therapy blood requirements - 🧠 ANSWER ✔✔60,000-100,000/ul
platelet
2400-3000/ul leukocyte
2000/ul granuolyte
I 131 MIBG - 🧠 ANSWER ✔✔metaiodobenzylguanidine
half life = 8.06 days
localization/treatment of primary or metastatic pheochromocytomas/
neuroblastoma
8.04 days
kidney/ urinary excretion
I 131 Sodium Iodide - 🧠 ANSWER ✔✔half life = 8.06 days
2025/2026 Exam Questions and Correct
Answers | New Update
Gas Ventilation - 🧠 ANSWER ✔✔Xe 133, 81 KeV, 5.3 half life; reactor
produced
dose: 10-20 mCi
imaging: posterior position
negative pressure room required
uses activated charcoal trap to accumulate the exhaled xenon gas until
decayed to background
single breath: during inhalation
wash in / equilibrium : collected while the xenon distributes through aerated
portions of the lung
,wash out : while radioactivity is cleared from lungs
Sr 89 Chloride - 🧠 ANSWER ✔✔Strontium Chloride, Metastron
1.46 MeV max, .58 Mev mean
half life = 50.5 days
40-60 uci/kg IV
for skeletal mets, depresses bone marrow
shouldn't be used if leukocyte count below 2400/ul or platelet below
60,o00/ul
excretion : urinary
I 131 Tositumomab - 🧠 ANSWER ✔✔Bexxar
half life = 8.04 days
606.3 KeV max energy
treatment of patients with NHL
before treatment, patient must receive 650 mg acetaminophen and 50mg
diphydramine orally
thyroid uptake should be minimized with SSKI
,activity initially seen in blood pool, liver and spleen
later times, activity in liver, spleen, thyroid, bladder, and tumor sites
Y 90 ibritumomab tiuxtetan - 🧠 ANSWER ✔✔Zevalin
half life = 2.67 days
2.281 MeV
treatment of patients with NHL (disseminated follicular B-Cell)
monoclonal antibody against lymphoma antigens
before treatment, patient must receive 650 mg (imaging) acetaminophen
and 50mg diphydramine orally
max dose = 32 mci
platelets must be at least 100,000/mm3
Sm 153 EDTMP - 🧠 ANSWER ✔✔ethylenediaminetetra methylene
phosphonic
Quadramet
half life = 46.7 hours
0.81 MeV maximum
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
PRIVACY STATEMENT. ALL RIGHTS RESERVED
, concentrates in bone marrow
for patients with more metabolically activate metastases from prostate or
breast cancer, as well as those from osteogenic sarcoma
1.0mci/kg
urinary excretion
Bone therapy blood requirements - 🧠 ANSWER ✔✔60,000-100,000/ul
platelet
2400-3000/ul leukocyte
2000/ul granuolyte
I 131 MIBG - 🧠 ANSWER ✔✔metaiodobenzylguanidine
half life = 8.06 days
localization/treatment of primary or metastatic pheochromocytomas/
neuroblastoma
8.04 days
kidney/ urinary excretion
I 131 Sodium Iodide - 🧠 ANSWER ✔✔half life = 8.06 days
